**Supplemental Figure 1: IL-23 levels are reduced in HDM asthmatic** *Tlr6<sup>-/-</sup>* **mice.** Transcript expression of *II23* in whole lungs of WT or *Tlr6<sup>-/-</sup>* mice challenged with HDM for 6 weeks. Data represent mean ±SEM of two independent experiments, and n=4-5 mice/group. \*P<0.05 compared to WT control mice.

Supplemental Figure 2: *Tlr6<sup>-/-</sup>* DCs have impaired ability to activate memory Th17 cells. Percentage of CD4<sup>+</sup>IL-17<sup>+</sup>T cells (A) and IL-17A levels (B) observed in coculture of WT and Tlr6-/- DCs with OTII transgenic Th17 cells differentiated in vitro for 6 days with anti-IL-4, anti-IFN- $\gamma$  and rTGF- $\beta$ . Data represents mean ± SEM of n=5 mice/group.

**Supplemental Figure 3:** TIr6-/- DCs have an impaired ability to express TGF-b. (A) Percentage of CD11c<sup>+</sup>CD11b<sup>+</sup>F4/80<sup>neg</sup> expressing LAP-TGF-b in lungs from WT and  $Tlr6^{-/-}$  mice at day 26 after conidia. (B) Transcript expression of *Tgfb1* in bone marrowderived DC from WT allergic mice stimulated in vitro with Aspergillus, ovalbumin, house dust mite or cochroach antigens in the presence of medium alone or anti-dectin-1 blocking antibody. (C) Transcript expression of *Tgfb1* in bone marrow-derived DC from WT and *Tlr6*<sup>-/-</sup> naive mice stimulated in vitro with different antigens. Data represents mean ± SEM of n=5 mice/group. \*p<0.05 compared to WT under the same condition or medium.



Supplemental Figure 1



Supplemental Figure 2

% of IL-17 producing T cells



## Supplemental Figure 3